
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies for serious diseases associated with dysregulated immune responses. With a market potential of nearly 1 billion dollars and positive top-line data from its Phase 2a study for IPF, GRI Bio's GRI-0621 has the potential to be a valuable treatment for autoimmune disorders and has shown promise in resolving fibrosis in patients. While there are risks associated with clinical trials and commercialization, the potential for high rewards make this stock a positive investment outlook.
Bears say
GRI Bio is facing a negative outlook due to its long development and commercialization roads for its two drugs, GRI-0621 and GRI-0803, and the high risks associated with clinical trials and commercial failures. Despite the potential for high rewards in the billion dollar market for IPF, concerns about the balance sheet/liquidity risks and the company's ability to obtain regulatory approvals and commercialize its products outweigh the potential for growth and valuation. Additionally, changing macroeconomic factors and investor sentiment towards biotech stocks may also pose risks to the company's share price. Ultimately, the potential for success is uncertain and presents significant risks for investors.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares